Published on 21/12/2025
Expanded Access and Compassionate Use Programs in U.S. Clinical Trials: Regulatory and Practical Insights
Introduction
Expanded Access (EA) and Compassionate Use programs allow patients with serious or life-threatening diseases to receive investigational drugs outside traditional clinical trials. In the United States, these programs are regulated by the Food and Drug Administration (FDA) under 21 CFR Part 312, ensuring that patients can access potentially beneficial therapies while maintaining safety oversight. EA is not a substitute for participation in clinical trials but serves as a pathway for those who cannot enroll in trials due to eligibility criteria, geographic barriers, or urgent medical need. This article examines the regulatory framework, operational processes, ethical considerations, and case studies that illustrate the role of Expanded Access in U.S. clinical development.
Background / Regulatory Framework
FDA Regulations
FDA regulates Expanded Access under 21 CFR 312.300–312.320. Three main pathways exist: (1) single-patient INDs (including emergency use), (2) intermediate-size patient populations, and (3) treatment IND or protocol for widespread access. Each requires sponsor and FDA approval, with oversight to ensure risk-benefit justification.
Right to Try Act
In 2018, the Right to Try Act created an alternative mechanism for patient access without FDA pre-approval. However, most
Case Example—Emergency IND
A physician filed an emergency IND for a patient with rapidly progressing leukemia. FDA responded within 24 hours, authorizing use of the investigational therapy. The case highlights FDA’s commitment to rapid patient access while maintaining oversight.
Core Clinical Trial Insights
1) Patient Eligibility
Patients must have serious or life-threatening conditions, lack comparable treatment options, and be unable to participate in clinical trials. The treating physician must determine potential benefit outweighs risks.
2) Sponsor Responsibilities
Sponsors must provide the investigational drug, agree to FDA reporting, and maintain manufacturing and supply chain integrity. They may decline requests due to supply constraints or trial priorities.
3) Investigator and IRB Roles
Physicians submitting EA requests must file Form FDA 3926 (single-patient IND). IRB review is required for most requests, except in emergencies where review may follow after treatment initiation.
4) FDA Review Timelines
FDA reviews non-emergency EA requests within 30 days but typically responds much faster, often within 4–5 days. Emergency requests can be approved in less than 24 hours.
5) Data Collection and Safety Reporting
EA use requires safety reporting to FDA, including adverse events. Data may not contribute to efficacy claims but provide valuable insights into safety profiles for regulatory submissions.
6) Ethical Considerations
EA raises ethical issues, including equitable access, patient expectations, and the balance between individual benefit and scientific rigor. Sponsors and physicians must manage communication carefully to avoid therapeutic misconception.
7) Impact on Clinical Development
While EA is not a substitute for trials, it can inform trial design and safety monitoring. FDA considers EA data supportive but not pivotal in approval decisions.
8) Financial Considerations
Sponsors may charge only direct costs for EA programs, subject to FDA approval. Cost recovery requests must include justification to FDA and avoid undue burden on patients.
9) Rare Disease and Oncology Applications
EA is frequently used in rare disease and oncology settings, where trial opportunities may be limited. FDA encourages sponsors to establish intermediate-size programs in these areas.
10) Communication with Stakeholders
Sponsors must maintain transparent communication with patients, physicians, FDA, and IRBs. Clear documentation and consistent updates are critical for compliance and trust.
Best Practices & Preventive Measures
Sponsors should: (1) establish SOPs for EA requests; (2) train investigators on FDA Form 3926; (3) predefine eligibility criteria; (4) maintain drug supply planning; (5) ensure IRB readiness; (6) document safety reporting rigorously; (7) communicate openly with patients; (8) align EA activities with global access programs; and (9) prepare inspection-ready records of all EA activities.
Scientific & Regulatory Evidence
Key references include 21 CFR 312.300–312.320, FDA guidance on Expanded Access (2017), FDA Form 3926 instructions, and the Right to Try Act (2018). ICH E6(R2) GCP also applies where EA overlaps with trial conduct.
Special Considerations
Pediatric, elderly, and rural populations may face unique barriers to EA. Sponsors should design programs that address equity and ensure vulnerable groups are not excluded from access opportunities.
When Sponsors Should Seek Regulatory Advice
Sponsors should consult FDA when designing intermediate-size or treatment IND programs, establishing cost recovery mechanisms, or introducing novel therapies under EA. Type C meetings provide opportunities to confirm expectations.
Case Studies
Case Study 1: Rare Disease EA Program
A biotech company established an intermediate-size EA program for a rare neuromuscular disorder. FDA approved the program, enabling access for dozens of patients while Phase 3 trials were ongoing.
Case Study 2: Oncology Compassionate Use
A cancer patient unable to join a Phase 2 trial accessed the investigational drug through EA. The sponsor collected valuable safety data, later included in the NDA safety analysis.
Case Study 3: COVID-19 Emergency IND
During the pandemic, FDA authorized emergency INDs for investigational antivirals and convalescent plasma, demonstrating the speed and flexibility of EA pathways in urgent situations.
FAQs
1) What is the difference between Expanded Access and clinical trials?
Expanded Access provides investigational drugs outside trials for patients lacking alternatives, while clinical trials are designed to generate efficacy and safety data.
2) What forms are used for single-patient EA requests?
FDA Form 3926 is required for physician submissions.
3) How quickly does FDA approve EA requests?
Non-emergency requests typically within 4–5 days; emergencies may be approved within 24 hours.
4) Can sponsors decline EA requests?
Yes, often due to limited supply, ongoing trials, or strategic considerations.
5) Does EA data count toward FDA approval?
Safety data are reviewed but efficacy data are generally not pivotal for approval decisions.
6) What role do IRBs play?
IRBs review consent and safety protections, except in emergencies where review may follow treatment initiation.
7) Is the Right to Try Act widely used?
No, most requests still go through FDA’s EA pathway due to stronger safety oversight.
Conclusion & Call-to-Action
Expanded Access and Compassionate Use programs provide vital pathways for patients unable to enroll in clinical trials. Sponsors and investigators must comply with FDA requirements, ensure ethical conduct, and maintain robust safety reporting. By establishing proactive EA programs and engaging FDA early, sponsors can balance patient access with regulatory compliance, contributing to both public health and clinical development success.